News | September 22, 2009

PROMUS, First-Generation TAXUS Express Stents Perform Strongly in SPIRIT III Trial

September 21, 2009 — Boston Scientific Corp. today welcomed three-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety of the Company's portfolio of drug-eluting stents, including the first-generation TAXUS Express(2) Paclitaxel-Eluting Coronary Stent System and the XIENCE V (PROMUS ) Everolimus-Eluting Coronary Stent

System. The results were presented at the Transcatheter Cardiovascular
Therapeutics (TCT) scientific symposium in San Francisco by Gregg W. Stone, M.D., professor of medicine and the director of research and education at the Center for Interventional Vascular Therapy at the Columbia University Medical Center/New York-Presbyterian Hospital, and principal investigator of the trial.

The results demonstrated that the XIENCE V (PROMUS) and TAXUS Express Stents had comparable safety outcomes through three years, with equivalent rates of cardiac death (1.4 versus 1.6 percent) and low and equivalent rates of stent thrombosis using the ARC (Academic Research Consortium) definite/probable definition (1.2 and 1.6 percent). No additional stent thromboses were reported between years two and three for either stent group.

The three-year rate of ischemia-driven target lesion revascularization (TLR) was lower for the XIENCE V (PROMUS) stent as compared to the TAXUS Express Stent (5.4 versus 8.9 percent), contributing to a benefit for XIENCE V (PROMUS) over the TAXUS Express Stent in the composite endpoints of major adverse cardiac events (MACE, a composite endpoint of cardiac death, myocardial infarction (MI) and TLR) (9.1 versus 15.7 percent) and target vessel failure (TVF, a composite endpoint of cardiac death, MI and ischemia-driven target vessel revascularization) (13.5 versus 19.2 percent).

The SPIRIT III results exhibited similar rates of safety and efficacy for the XIENCE V (PROMUS) and TAXUS Express Stents in diabetic patients, with TLR rates of 5.2 versus 4.8 percent and MACE rates of 10.3 percent versus 9.4 percent. The rate of TLR for TAXUS Express diabetic patients was 4.8 percent as compared to 10.5 percent in nondiabetic TAXUS Express patients.

The PROMUS Stent is a private-labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. SPIRIT III is sponsored by Abbott. TAXUS, TAXUS Express2, Express and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott Laboratories Group of Companies.

The safety and effectiveness of the TAXUS Express Stent has not been established in diabetic patients. Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init